Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 20;12:975980. doi: 10.3389/fonc.2022.975980

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Benitez Fuentes, Mohamed Mohamed, de Luna Aguilar, Jiménez García, Guevara-Hoyer, Fernandez-Arquero, Rodríguez de la Peña, Garciía Bravo, Jiménez Ortega, Flores Navarro, Bartolome Arcilla, Alonso Arenilla, Baos Muñoz, Delgado-Iribarren García-Campero, Montealegre Sanz, Sanchez-Ramon and Perez Segura

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Specific anti-SARS-CoV-2 IFN-γ responses measured by IGRA. Dotted lines represent positivity cut-off: ≥200 mUI/ml. (A) All cancer patients. Significant differences were seen in cancer patients between the baseline anti-SARS-CoV-2 IFN-γ titres and after the second (p<0.001) and third vaccine doses (p<0.001). Two groups were established after the third dose according to the pattern of cellular behavior: one that enhanced their IFN-γ titres after the third vaccine dose (Group 1); and Group 2 that displayed a drastic fall-off of specific anti-SARS-CoV-2 IFN-γ titres. (B) Group 1 cancer patients. (C) Group 2 cancer patients. *P<0.05 **P<0.01 ***P<0.001.